Previous close | 0.2800 |
Open | 0.3500 |
Bid | 0.2800 |
Ask | 0.4200 |
Strike | 5.00 |
Expiry date | 2025-01-17 |
Day's range | 0.2500 - 0.3500 |
Contract range | N/A |
Volume | |
Open interest | 17.87k |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.